RecruitingNCT07558889
The Surveillance, Epidemiology, and End Results Database Program on Endometrial Cancer in the Italian Population
The ENDOCancer-DATA: the Surveillance, Epidemiology, and End Results Database Program on Endometrial Cancer in the Italian Population
Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Enrollment
10,000 participants
Start Date
Apr 1, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
The aim of this study is to lay the bases for an ambitious project that reports and records all the epidemiological-clinical information of the cases of endometrial carcinoma diagnosed and treated in the reference oncology centers involved on the national territory, to create a process of analysis of the data
Eligibility
Sex: FEMALEMin Age: 18 Years
Inclusion Criteria5
- diagnosis of endometrial cancer (stage I-IV, G1-3, and special histotypes)
- age > 18 years
- American Society of Anesthesiologists classification (ASA score) 1-3
- patients undergoing staging, cytoreduction or diagnostic surgery with acquisition of histological examination on which IHC and/or NGS studies have been performed for the molecular profile of the carcinoma
- Signed informed consent
Exclusion Criteria3
- patients with missing information
- patients not treated in the participating centers for which only partial and fragmented information will be available
- molecular profile not known and\\or not recoverable and retrospectively analysable
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07558889
Related Trials
Cryocompression to Reduce Chemotherapy-induced Peripheral Neuropathy in Gynecologic Cancer - COHORT 2
NCT061394584 locations
Transcranial Magnetic Stimulation for Chemotherapy-Induced Peripheral Neuropathy in Breast and Gynecologic Cancer Survivors
NCT071201001 location
Pilot Observational Study of an Integrative Cure Stay Program
NCT073980791 location
Brodalumab in the Treatment of Immune-Related Adverse Events
NCT066733291 location
Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)
NCT075241141 location